Bottom line
JDOC vs ETHSX: the short answer
JDOC (JPMorgan Healthcare Leaders ETF) and ETHSX (Eaton Vance Worldwide Health Sciences Fund) share a meaningful slice of their top holdings — about 63% by weight.
JDOC is cheaper at 0.65% vs 1.18% — a difference of $53 a year per $10,000 invested.
Over one year, JDOC returned +14.9% vs −1.9% for ETHSX (reporting dates differ).
ETHSX has a front-end sales load of up to 5.25%; the other does not.
Updated Nov 19, 2026
JDOC vs ETHSX side by side
| JDOC | ETHSX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | J.P. Morgan | Morgan Stanley |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.65% | 1.18% |
| Annual cost per $10k | $65 | $118 |
| 10-yr cost on $10k (prospectus) | $810 | $1,911 |
| Max front load | None | 5.25% |
| 12b-1 fee | — | 0.25% |
| 1-yr return | +14.9% | −1.9% |
| 5-yr return (annualized) | — | +5.3% |
| 10-yr return (annualized) | — | +6.4% |
| Best quarter | +11.3% | +14.2% |
| Worst quarter | −11.9% | −12.1% |
| Net assets (fund) | $9.1M | $757.9M |
| Number of holdings | 61 | 42 |
| Portfolio turnover | 92% | 3% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | JDOC | ETHSX | Difference |
|---|---|---|---|
| 2024 | −0.6% | +3.5% | −4.2% |
Source: Fund prospectus bar charts
Holdings overlap
14 of JDOC's top 25 holdings also appear in ETHSX's top 25.
| Holding | JDOC | ETHSX |
|---|---|---|
| AbbVie, Inc. | 7.85% | 6.46% |
| Eli Lilly & Co. | 7.76% | 12.47% |
| UnitedHealth Group, Inc. | 5.85% | 5.49% |
| Merck & Co., Inc. | 4.82% | 5.08% |
| Johnson & Johnson | 4.82% | 6.45% |
| AstraZeneca plc | 3.76% | 6.24% |
| Thermo Fisher Scientific, Inc. | 3.73% | 2.79% |
| Bristol-Myers Squibb Co. | 3.57% | 4.25% |
| Abbott Laboratories | 3.11% | 1.65% |
| Roche Holding AG | 2.82% | 5.44% |
| Novo Nordisk A/S | 2.61% | 1.71% |
| Stryker Corp. | 2.23% | 2.21% |
| Intuitive Surgical, Inc. | 1.93% | 2.72% |
| Novartis AG | 1.60% | 1.65% |
Source: SEC Form N-PORT
JDOC top 10
- AbbVie, Inc. — 7.85%
- Eli Lilly & Co. — 7.76%
- UnitedHealth Group, Inc. — 5.85%
- Merck & Co., Inc. — 4.82%
- Johnson & Johnson — 4.82%
- AstraZeneca plc — 3.76%
- Thermo Fisher Scientific, Inc. — 3.73%
- Bristol-Myers Squibb Co. — 3.57%
- Abbott Laboratories — 3.11%
- CVS Health Corp. — 2.83%
ETHSX top 10
- Eli Lilly & Co — 12.47%
- AbbVie Inc — 6.46%
- Johnson & Johnson — 6.45%
- AstraZeneca PLC — 6.24%
- UnitedHealth Group Inc — 5.49%
- Roche Holding AG — 5.44%
- Merck & Co Inc — 5.08%
- Bristol-Myers Squibb Co — 4.25%
- Vertex Pharmaceuticals Inc — 3.38%
- Gilead Sciences Inc — 3.34%
FAQ
What is the difference between JDOC and ETHSX?
Which is cheaper, JDOC or ETHSX?
Should I own both JDOC and ETHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.